Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is attractive fundamentally because its FDA-cleared RenovoCath is already being commercialized, with active cancer centers rising from 5 in September 2025 to 16 currently and a target of 36 by the end of 2026, supporting revenue estimates of $2.8 million in 2026 and $4.5 million in 2027. Its proprietary TAMP platform addresses a large unmet need by delivering therapy directly to the tumor site, which could improve safety, tolerance, and efficacy versus systemic IV treatment, while the ongoing Phase III TIGeR-PaC trial has advanced after the DMC recommended continuation following the August 2025 second interim review and positive March 2023 first interim results. Financially, the company appears adequately funded with $12 million in cash and no debt after raising $10 million in Q1, and the combination of a potentially billion-dollar market opportunity, upcoming enrollment completion in June 2026, and final data in mid to late 2027 supports a favorable long-term outlook.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with compelling scientific ambition, but its investment case is weakened by major execution and financing risks that could prevent it from converting its platform into commercial value. The company itself highlights balance sheet and liquidity risk, uncertainty around safety and efficacy in clinical trials, regulatory approval hurdles, commercialization challenges, reimbursement uncertainty, and intense competition, all of which can delay or derail adoption of its intra-arterial delivery approach. Even with pancreatic cancer’s 12% 5-year combined overall survival rate underscoring the unmet need, the absence of proven late-stage clinical success leaves the stock highly dependent on outcomes that remain unconfirmed.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Oct 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.